Fidelity Investments’s Royalty Pharma RPRX Stock Holding History

Fidelity Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37B	Sell	24,513,814 -638,428	-3%	-$33.2M	0.06%	240
2026 Q1	$1.21B	Sell	25,152,242 -1,120,066	-4%	-$49.1M	0.06%	245
2025 Q4	$1.02B	Sell	26,272,308 -1,714,406	-6%	-$65.4M	0.05%	299
2025 Q3	$987M	Sell	27,986,714 -12,371,107	-31%	-$448M	0.05%	299
2025 Q2	$1.45B	Buy	40,357,821 +953,728	+2%	+$31.6M	0.08%	201
2025 Q1	$1.23B	Buy	39,404,093 +13,024,760	+49%	+$413M	0.08%	216
2024 Q4	$673M	Sell	26,379,333 -1,510,810	-5%	-$40.1M	0.04%	365
2024 Q3	$789M	Buy	27,890,143 +3,442	+0%	+$95.3K	0.05%	334
2024 Q2	$735M	Sell	27,886,701 -5,747,515	-17%	-$159M	0.05%	328
2024 Q1	$1.02B	Buy	33,634,216 +2,050,287	+6%	+$60.4M	0.07%	256
2023 Q4	$887M	Buy	31,583,929 +1,156,757	+4%	+$31.8M	0.07%	257
2023 Q3	$826M	Sell	30,427,172 -3,457,078	-10%	-$103M	0.07%	242
2023 Q2	$1.04B	Sell	33,884,250 -6,099,866	-15%	-$207M	0.09%	204
2023 Q1	$1.44B	Sell	39,984,116 -4,126,249	-9%	-$153M	0.13%	136
2022 Q4	$1.74B	Buy	44,110,365 +1,152,485	+3%	+$48.1M	0.17%	106
2022 Q3	$1.73B	Buy	42,957,880 +7,004,526	+19%	+$299M	0.18%	96
2022 Q2	$1.51B	Buy	35,953,354 +7,748,193	+27%	+$318M	0.15%	126
2022 Q1	$1.1B	Buy	28,205,161 +6,125,366	+28%	+$241M	0.09%	205
2021 Q4	$880M	Buy	22,079,795 +2,970,038	+16%	+$115M	0.07%	282
2021 Q3	$691M	Sell	19,109,757 -4,986,172	-21%	-$194M	0.05%	324
2021 Q2	$988M	Sell	24,095,929 -3,856,891	-14%	-$164M	0.08%	233
2021 Q1	$1.22B	Buy	27,952,820 +3,010,272	+12%	+$143M	0.1%	181
2020 Q4	$1.25B	Buy	24,942,548 +6,754,244	+37%	+$287M	0.11%	168
2020 Q3	$754M	Buy	18,188,304 +1,831,813	+11%	+$78.6M	0.08%	228
2020 Q2	$743M	Buy	+16,356,491	New	+$810M	0.08%	217

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Fidelity Investments's RPRX Position: Q2 2026 in Review

Fidelity Investments reduced its Royalty Pharma (RPRX) stake by 2.5% in Q2 2026, selling an estimated $33.2M and leaving 24,513,814 shares worth $1.37B. The position accounts for 0.06% of the portfolio, ranked #240.

Fidelity Investments first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.74B in Q4 2022. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Fidelity Investments held 24,513,814 shares of Royalty Pharma worth $1.37B as of Q2 2026.
Fidelity Investments sold 638,428 Royalty Pharma shares in Q2 2026, an estimated $33.2M.
Royalty Pharma made up 0.06% of Fidelity Investments's portfolio in Q2 2026, its #240 holding.
Fidelity Investments first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
Fidelity Investments's Royalty Pharma position peaked at $1.74B in Q4 2022.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.